ALAB-P A-Labs Capital II Corp.
0.0419USD0.0600 CAD · TSXV0.00%Mkt Cap: 325597 USDP/E: —2d ago
Industry Peers
Drug Manufacturers - GeneralKey Statistics
Company
Market Cap325.60K USD
Enterprise Value—
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-31.46K USD
Revenue/Share—
Last Price0.0419 USD
Fiscal Year End—
MR Quarter—
Employees—
CountryCA
SectorHealthcare
IndustryDrug Manufacturers - General
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B-1.58
EPS (TTM)—
EPS (Forward)—
52W Range
0.031514% of range0.1049
52W High0.1049 USD
52W Low0.0315 USD
Profitability
Gross Margin—
Oper. Margin—
EBITDA Margin—
Profit Margin—
ROE19.19%
ROA-179.49%
ROIC—
ROCE—
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-89.87K USD
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt—
Net Debt/EBITDA—
Net Debt/FCF—
Balance Sheet
Debt/Equity-0.65
Current Ratio—
Quick Ratio—
Book Value/Sh-0.03 USD
Cash/Share—
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.7.76M
Float—
Insiders—
Institutions—
Technical
SMA 500.0440 (-4.8%)
SMA 2000.0419 (+0.2%)
Beta—
S&P 52W Chg—
Avg Vol (30d)2.47K
Avg Vol (10d)1.91K
Technical Indicators
RSI (14)39.2
MACD-0.0012
MACD Signal-0.0004
MACD Hist.-0.0007
BB Upper0.0579 USD
BB Middle0.0454 USD
BB Lower0.0330 USD
BB Width54.68%
ATR (14)0.0009 USD
Vol Ratio (20d)0.00x
About A-Labs Capital II (CVE: ALAB-P)
›
A-Labs Capital II (CVE: ALAB-P) is listed on the TSX Venture Exchange, where its shares trade in CAD. It belongs to the Drug Manufacturers - General industry, part of the Healthcare sector.
The shares were at 0.0600 CAD on 18 November 2026, down 20.0% over 52 weeks. Its 52-week range is 0.0450 CAD to 0.1500 CAD: the price is 60.0% below the high and 33.3% above the low.
Its market capitalisation is 465.77K CAD.
A-Labs Capital II reports return on equity of 19.2%.
Its Piotroski F-score is 4 out of 9, an average reading of its financial health. The next earnings report is expected on 26 November 2026.